Page 1

Clinical Update : Results from 30 mg / kg Cohort of MOMENTUM Study of SRP - 5051 for Duchenne Muscular Dystrophy DOUG INGRAM President and CEO May 3 , 2021 8:30 a.m. ET GILMORE O'NEILL , MB , MMSC Executive Vice President , R & D and Chief Medical Officer go SAREPTA THERAPEUTICS OSAREPTA THERAPEUTICS , INC . 2021. ALL RIGHTS RESERVED . 1